Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 159

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

AGC kinases, mechanisms of regulation and innovative drug development

Leroux, Alejandro E., Schulze, Jörg O., Biondi, Ricardo M. · 2018 · Seminars in Cancer Biology

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2017.05.011

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 167

  1. Pawson, 2005, Protein phosphorylation in signaling–50 years and counting, Trends Biochem. Sci., 30, 286, 10.1016/j.tibs.2005.04.013 · DOI · Paper page
  2. Manning, 2002, The protein kinase complement of the human genome, Science, 298, 1912, 10.1126/science.1075762 · DOI · Paper page
  3. Arencibia, 2013, AGC protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases, Biochim. Biophys. Acta, 1834, 1302, 10.1016/j.bbapap.2013.03.010 · DOI · Paper page
  4. Zhang, 2009, AGCVIII kinases: at the crossroads of cellular signaling, Trends Plant Sci., 14, 689, 10.1016/j.tplants.2009.09.006 · DOI
  5. Cohen, 2002, Protein kinases–the major drug targets of the twenty-first century?, Nat. Rev. Drug Discov., 1, 309, 10.1038/nrd773 · DOI · Paper page
  6. Hergovich, 2013, Regulation and functions of mammalian LATS/NDR kinases: looking beyond canonical Hippo signalling, Cell Biosci., 3, 32, 10.1186/2045-3701-3-32 · DOI
  7. Rath, 2012, Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy, EMBO Rep., 13, 900, 10.1038/embor.2012.127 · DOI · Paper page
  8. Turnham, 2016, Protein kinase A catalytic subunit isoform PRKACA; History, function and physiology, Gene, 577, 101, 10.1016/j.gene.2015.11.052 · DOI · Paper page
  9. Pretre, 2017, Inhibition of Akt and other AGC kinases: a target for clinical cancer therapy?, Semin. Cancer Biol.
  10. Lindsley, 2014, Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites, J. Med. Chem., 57, 7485, 10.1021/jm5011786 · DOI
  11. Knighton, 1991, Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase, Science, 253, 407, 10.1126/science.1862342 · DOI · Paper page
  12. Taylor, 2013, PKA: lessons learned after twenty years, Biochim. Biophys. Acta., 1834, 1271, 10.1016/j.bbapap.2013.03.007 · DOI · Paper page
  13. Zheng, 1993, Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor, Biochemistry, 32, 2154, 10.1021/bi00060a005 · DOI · Paper page
  14. Huse, 2002, The conformational plasticity of protein kinases, Cell, 109, 275, 10.1016/S0092-8674(02)00741-9 · DOI · Paper page
  15. Kornev, 2015, Dynamics-driven allostery in protein kinases, Trends Biochem. Sci., 40, 628, 10.1016/j.tibs.2015.09.002 · DOI · Paper page
  16. Hindie, 2009, Structure and allosteric effects of low molecular weight activators on the protein kinase PDK1, Nat. Chem. Biol., 5, 758, 10.1038/nchembio.208 · DOI
  17. Leslie, 2001, Phosphoinositide-regulated kinases and phosphoinositide phosphatases, Chem. Rev., 101, 2365, 10.1021/cr000091i · DOI
  18. Newton, 2003, Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm, Biochem. J., 370, 361, 10.1042/bj20021626 · DOI · Paper page
  19. Yang, 2002, Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP, Nat. Struct. Biol., 9, 940, 10.1038/nsb870 · DOI · Paper page
  20. Kemp, 1975, Substrate specificity of the cyclic AMP-dependent protein kinase, Proc. Natl. Acad. Sci. U. S. A., 72, 3448, 10.1073/pnas.72.9.3448 · DOI · Paper page
  21. Pinna, 1996, How do protein kinases recognize their substrates?, Biochim. Biophys. Acta, 1314, 191, 10.1016/S0167-4889(96)00083-3 · DOI · Paper page
  22. Biondi, 2000, Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA, EMBO J., 19, 979, 10.1093/emboj/19.5.979 · DOI · Paper page
  23. Biondi, 2002, High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site, EMBO J., 21, 4219, 10.1093/emboj/cdf437 · DOI · Paper page
  24. Hauge, 2007, Mechanism for activation of the growth factor-activated AGC kinases by turn motif phosphorylation, EMBO J., 26, 2251, 10.1038/sj.emboj.7601682 · DOI
  25. Nolen, 2004, Regulation of protein kinases; controlling activity through activation segment conformation, Mol. Cell, 15, 661, 10.1016/j.molcel.2004.08.024 · DOI · Paper page
  26. Dettori, 2009, Regulation of the interaction between protein kinase C-related protein kinase 2 (PRK2) and its upstream kinase: 3-phosphoinositide-dependent protein kinase 1 (PDK1), J. Biol. Chem., 284, 30318, 10.1074/jbc.M109.051151 · DOI
  27. Yang, 2002, Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation, Mol. Cell, 9, 1227, 10.1016/S1097-2765(02)00550-6 · DOI · Paper page
  28. Zhang, 2014, Molecular mechanism of regulation of the atypical protein kinase C by N-terminal domains and an allosteric small compound, Chem. Biol., 21, 754, 10.1016/j.chembiol.2014.04.007 · DOI
  29. Hindie, 2012, Use of a fluorescent ATP analog to probe the allosteric conformational change in the active site of the protein kinase PDK1, Methods Mol. Biol., 928, 133, 10.1007/978-1-62703-008-3_10 · doi:10.1007/978-1-62703-008-3_10
  30. Busschots, 2012, Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-Pocket allosteric docking site, Chem. Biol., 19, 1152, 10.1016/j.chembiol.2012.07.017 · DOI
  31. Lopez-Garcia, 2011, Allosteric regulation of protein kinase PKCzeta by the N-terminal C1 domain and small compounds to the PIF-pocket, Chem. Biol., 18, 1463, 10.1016/j.chembiol.2011.08.010 · DOI
  32. Bauer, 2012, Regulation of protein kinase C-related protein kinase 2 (PRK2) by an intermolecular PRK2-PRK2 interaction mediated by its N-terminal domain, J. Biol. Chem., 287, 20590, 10.1074/jbc.M111.327437 · DOI
  33. Baumli, 2008, The structure of P-TEFb (CDK9/cyclin T1): its complex with flavopiridol and regulation by phosphorylation, EMBO J., 27, 1907, 10.1038/emboj.2008.121 · DOI · Paper page
  34. Jura, 2011, Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms, Mol. Cell, 42, 9, 10.1016/j.molcel.2011.03.004 · DOI · Paper page
  35. Frodin, 2000, A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1, EMBO J., 19, 2924, 10.1093/emboj/19.12.2924 · DOI · Paper page
  36. Biondi, 2001, The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK: but not PKB, EMBO J., 20, 4380, 10.1093/emboj/20.16.4380 · DOI · Paper page
  37. Stegert, 2004, Regulation of NDR2 protein kinase by multi-site phosphorylation and the S100B calcium-binding protein, J. Biol. Chem., 279, 23806, 10.1074/jbc.M402472200 · DOI
  38. Cook, 2014, Constitutively active NDR1-PIF kinase functions independent of MST1 and hMOB1 signalling, Cell. Signal., 26, 1657, 10.1016/j.cellsig.2014.04.011 · DOI
  39. Hoa, 2016, The characterisation of LATS2 kinase regulation in Hippo-YAP signalling, Cell. Signal., 28, 488, 10.1016/j.cellsig.2016.02.012 · DOI
  40. Sadowsky, 2011, Turning a protein kinase on or off from a single allosteric site via disulfide trapping, Proc. Natl. Acad. Sci. U S A, 108, 6056, 10.1073/pnas.1102376108 · DOI
  41. Frohner, 2011, 4-Benzimidazolyl-3-phenylbutanoic acids as novel pif-pocket-targeting allosteric inhibitors of protein kinase PKCzeta, J. Med. Chem., 54, 6714, 10.1021/jm2005892 · DOI
  42. Stroba, 2009, 3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds, J. Med. Chem., 52, 4683, 10.1021/jm9001499 · DOI
  43. Engel, 2006, Allosteric activation of the protein kinase PDK1 with low molecular weight compounds, EMBO J., 25, 5469, 10.1038/sj.emboj.7601416 · DOI
  44. Wilhelm, 2012, 2-(3-Oxo-1,3-diphenylpropyl)malonic acids as potent allosteric ligands of the PIF pocket of phosphoinositide-dependent kinase-1: development and prodrug concept, J. Med. Chem., 55, 9817, 10.1021/jm3010477 · DOI
  45. Schulze, 2016, Bidirectional allosteric communication between the ATP-binding site and the regulatory PIF pocket in PDK1 protein kinase, Cell Chem. Biol., 23, 1193, 10.1016/j.chembiol.2016.06.017 · DOI · Paper page
  46. Kroon, 2015, Discovery of a potent allosteric kinase modulator by combining computational and synthetic methods, Angew. Chem. Int. Ed., 54, 13933, 10.1002/anie.201506310 · DOI
  47. Rettenmaier, 2014, A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1, Proc. Natl. Acad. Sci. U. S. A., 111, 18590, 10.1073/pnas.1415365112 · DOI
  48. Stockman, 2009, Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments, Chem. Biol. Drug Des., 73, 179, 10.1111/j.1747-0285.2008.00768.x · DOI
  49. Wei, 2010, Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1, Bioorg. Med. Chem. Lett., 20, 3897, 10.1016/j.bmcl.2010.05.019 · DOI
  50. Gagliardi, 2015, PDK1: a signaling hub for cell migration and tumor invasion, Biochim. Biophys. Acta, 1856, 178
  51. Armando, 2017, PDK1: at the crossroad of cancer signaling pathways, Semin. Cancer Biol.
  52. Vanhaesebroeck, 2000, The PI3K-PDK1 connection: more than just a road to PKB, Biochem. J., 346, 561, 10.1042/bj3460561 · doi:10.1042/bj3460561 · Paper page
  53. Zurashvili, 2013, Interaction of PDK1 with phosphoinositides is essential for neuronal differentiation but dispensable for neuronal survival, Mol. Cell. Biol., 33, 1027, 10.1128/MCB.01052-12 · DOI
  54. Bayascas, 2008, Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways, Cell Cycle, 7, 2978, 10.4161/cc.7.19.6810 · DOI
  55. McManus, 2004, The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation, EMBO J., 23, 2071, 10.1038/sj.emboj.7600218 · DOI
  56. Lucas, 2011, Phosphatidylserine binding is essential for plasma membrane recruitment and signaling function of 3-phosphoinositide-dependent kinase-1, J. Biol. Chem., 286, 41265, 10.1074/jbc.M111.300806 · DOI
  57. Vonkova, 2015, Lipid cooperativity as a general membrane-recruitment principle for PH domains, Cell Rep., 12, 1519, 10.1016/j.celrep.2015.07.054 · DOI
  58. King, 2000, Sphingosine is a novel activator of 3-phosphoinositide-dependent kinase 1, J. Biol. Chem., 275, 18108, 10.1074/jbc.M909663199 · DOI
  59. Pastor-Flores, 2016, Lipid regulators of Pkh2 in Candida albicans, the protein kinase ortholog of mammalian PDK1, Biochim. Biophys. Acta-Mol. Cell Biology Lipids, 1861, 249, 10.1016/j.bbalip.2015.12.016 · DOI
  60. Pastor-Flores, 2013, PIF-pocket as a target for C. albicans Pkh selective inhibitors, ACS Chem. Biol., 8, 2283, 10.1021/cb400452z · DOI
  61. Masters, 2010, Regulation of 3-phosphoinositide-dependent protein kinase 1 activity by homodimerization in live cells, Sci. Signal., 3, ra78, 10.1126/scisignal.2000738 · DOI
  62. Kang, 2013, Transition from heterotypic to homotypic PDK1 homodimerization is essential for TCR-mediated NF-kappaB activation, J. Immunol., 190, 4508, 10.4049/jimmunol.1202923 · DOI
  63. Calleja, 2014, Acute regulation of PDK1 by a complex interplay of molecular switches, Biochem. Soc. Trans., 42, 1435, 10.1042/BST20140222 · DOI
  64. Balendran, 2000, A 3-phosphoinositide-dependent protein kinase-1 (PDK1) docking site is required for the phosphorylation of protein kinase Czeta (PKCzeta) and PKC-related kinase 2 by PDK1, J. Biol. Chem., 275, 20806, 10.1074/jbc.M000421200 · DOI · Paper page
  65. Collins, 2003, In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation, EMBO J., 22, 4202, 10.1093/emboj/cdg407 · DOI · Paper page
  66. Gao, 2001, The carboxyl terminus of protein kinase c provides a switch to regulate its interaction with the phosphoinositide-dependent kinase: PDK-1, J. Biol. Chem., 276, 19588, 10.1074/jbc.M101357200 · DOI
  67. Toker, 2000, Cellular signaling: pivoting around PDK-1, Cell, 103, 185, 10.1016/S0092-8674(00)00110-0 · DOI · Paper page
  68. Dutil, 1998, Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1), Curr. Biol., 8, 1366, 10.1016/S0960-9822(98)00017-7 · DOI · Paper page
  69. Bayascas, 2006, Evaluation of approaches to generation of tissue-specific knock-in mice, J. Biol. Chem., 281, 28772, 10.1074/jbc.M606789200 · DOI
  70. Collins, 2005, In vivo role of the phosphate groove of PDK1 defined by knockin mutation, J. Cell Sci., 118, 5023, 10.1242/jcs.02617 · DOI
  71. Balzano, 2015, Alternative activation mechanisms of protein kinase B trigger distinct downstream signaling responses, J. Biol. Chem., 290, 24975, 10.1074/jbc.M115.651570 · DOI
  72. Najafov, 2011, Characterization of GSK2334470: a novel and highly specific inhibitor of PDK1, Biochem. J., 433, 357, 10.1042/BJ20101732 · DOI
  73. Toker, 2014, Signaling specificity in the Akt pathway in biology and disease, Adv. Biol. Regul., 55, 28, 10.1016/j.jbior.2014.04.001 · DOI · Paper page
  74. Hers, 2011, Akt signalling in health and disease, Cell. Signal., 23, 1515, 10.1016/j.cellsig.2011.05.004 · DOI · Paper page
  75. Bozulic, 2009, PIKKing on PKB: regulation of PKB activity by phosphorylation, Curr. Opin. Cell Biol., 21, 256, 10.1016/j.ceb.2009.02.002 · DOI · Paper page
  76. Wu, 2010, Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition, PLoS One, 5, e12913, 10.1371/journal.pone.0012913 · DOI · Paper page
  77. Ebner, 2017, PI(3,4,5)P3 engagement restricts akt activity to cellular membranes, Mol. Cell, 65, 416, 10.1016/j.molcel.2016.12.028 · DOI · Paper page
  78. Mattmann, 2011, Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape, Expert. Opin. Ther. Pat., 21, 1309, 10.1517/13543776.2011.587959 · DOI
  79. Nitulescu, 2016, Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use (Review), Int. J. Oncol., 48, 869, 10.3892/ijo.2015.3306 · DOI · Paper page
  80. Lindsley, 2005, Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors, Bioorg. Med. Chem. Lett., 15, 761, 10.1016/j.bmcl.2004.11.011 · DOI · Paper page
  81. Lapierre, 2016, Discovery of 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin -2-amine (ARQ 092): an orally bioavailable, selective, and potent allosteric AKT inhibitor, J. Med. Chem., 59, 6455, 10.1021/acs.jmedchem.6b00619 · DOI
  82. Dudley, 1995, A synthetic inhibitor of the mitogen-activated protein kinase cascade, Proc. Natl. Acad. Sci. U. S. A., 92, 7686, 10.1073/pnas.92.17.7686 · DOI · Paper page
  83. Alessi, 1995, PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo, J. Biol. Chem., 270, 27489, 10.1074/jbc.270.46.27489 · DOI · Paper page
  84. Lu, 2015, The mechanism of ATP-dependent allosteric protection of akt kinase phosphorylation, Structure, 23, 1725, 10.1016/j.str.2015.06.027 · DOI · Paper page
  85. Rosse, 2010, PKC and the control of localized signal dynamics, Nat. Rev. Mol. Cell Biol., 11, 103, 10.1038/nrm2847 · DOI · Paper page
  86. Kazanietz, 2005, Targeting protein kinase C and non-kinase phorbol ester receptors: emerging concepts and therapeutic implications, Biochim. Biophys. Acta, 1754, 296, 10.1016/j.bbapap.2005.07.034 · DOI
  87. Antal, 2015, Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor, Cell, 160, 489, 10.1016/j.cell.2015.01.001 · DOI · Paper page
  88. AC, 2017, Protein kinase C as a tumor suppressor, Semin. Cancer Biol.
  89. Garg, 2014, Protein kinase C and cancer: what we know and what we do not, Oncogene, 33, 5225, 10.1038/onc.2013.524 · DOI · Paper page
  90. Kazanietz, 2011, Protein kinase C regulation: C1 meets C-tail, Structure, 19, 144, 10.1016/j.str.2011.01.004 · DOI
  91. Newton, 2010, Protein kinase C: poised to signal, Am. J. Physiol. Endocrinol. Metab., 298, E395, 10.1152/ajpendo.00477.2009 · DOI · Paper page
  92. Parker, 2001, AGC protein kinase phosphorylation and protein kinase C, Biochem. Soc. Trans., 29, 860, 10.1042/bst0290860 · DOI
  93. Parker, 2014, Atypical protein kinase Ciota as a human oncogene and therapeutic target, Biochem. Pharmacol., 88, 1, 10.1016/j.bcp.2013.10.023 · DOI
  94. Murray, 2011, Protein kinase Ciota expression and oncogenic signaling mechanisms in cancer, J. Cell. Physiol., 226, 879, 10.1002/jcp.22463 · DOI
  95. Farese, 2012, Atypical protein kinase C in cardiometabolic abnormalities, Curr. Opin. Lipidol., 23, 175, 10.1097/MOL.0b013e328352c4c7 · DOI
  96. Sommese, 2017, The Role of Regulatory Domains in Maintaining Autoinhibition in the Multidomain Kinase PKCalpha, J. Biol. Chem., 292, 2873, 10.1074/jbc.M116.768457 · DOI
  97. Kirwan, 2003, Inhibition of protein kinase C catalytic activity by additional regions within the human protein kinase Calpha-regulatory domain lying outside of the pseudosubstrate sequence, Biochem. J., 373, 571, 10.1042/bj20030011 · doi:10.1042/bj20030011
  98. Leonard, 2011, Crystal structure and allosteric activation of protein kinase C betaII, Cell, 144, 55, 10.1016/j.cell.2010.12.013 · DOI · Paper page
  99. Lucic, 2016, Novel features of DAG-activated PKC isozymes reveal a conserved 3-D architecture, J. Mol. Biol., 428, 121, 10.1016/j.jmb.2015.11.001 · DOI
  100. Antal, 2015, Intramolecular C2 domain-mediated autoinhibition of protein kinase C betaII, Cell Rep., 12, 1252, 10.1016/j.celrep.2015.07.039 · DOI
  101. Arencibia, 2017, An Allosteric Inhibitor Scaffold Targeting the PIF-Pocket of Atypical Protein Kinase C Isoforms, ACS Chem. Biol., 12, 564, 10.1021/acschembio.6b00827 · DOI
  102. O'Sullivan, 2017, Regulation of protein kinase C-related kinase (PRK) signalling by the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor: Implications for thromboxane- and androgen- dependent neoplastic and epigenetic responses in prostate cancer, Biochim Biophys Acta, 1863, 838, 10.1016/j.bbadis.2017.01.011 · DOI
  103. Davies, 2000, Specificity and mechanism of action of some commonly used protein kinase inhibitors, Biochem. J., 351, 95, 10.1042/bj3510095 · DOI · Paper page
  104. Lachmann, 2011, Regulatory domain selectivity in the cell-type specific PKN-dependence of cell migration, PLoS One, 6, e21732, 10.1371/journal.pone.0021732 · DOI
  105. Shiga, 2009, Development of an intracellularly acting inhibitory peptide selective for PKN, Biochem. J., 425, 445, 10.1042/BJ20090380 · DOI
  106. Mukai, 2003, The structure and function of PKN: a protein kinase having a catalytic domain homologous to that of PKC, J. Biochem., 133, 17, 10.1093/jb/mvg019 · DOI · Paper page
  107. Flynn, 2000, Rho GTPase control of protein kinase C-related protein kinase activation by 3-phosphoinositide-dependent protein kinase, J. Biol. Chem., 275, 11064, 10.1074/jbc.275.15.11064 · DOI
  108. Keshwani, 2011, Hydrophobic motif phosphorylation is not required for activation loop phosphorylation of p70 ribosomal protein S6 kinase 1 (S6K1), J. Biol. Chem., 286, 23552, 10.1074/jbc.M111.258004 · DOI
  109. Romeo, 2012, Regulation and function of the RSK family of protein kinases, Biochem. J., 441, 553, 10.1042/BJ20110289 · DOI · Paper page
  110. Houles, 2017, Defining the role of the RSK isoforms in cancer, Semin. Cancer Biol.
  111. Hauge, 2006, RSK and MSK in MAP kinase signalling, J. Cell Sci., 119, 3021, 10.1242/jcs.02950 · DOI · Paper page
  112. Weng, 1995, Multiple independent inputs are required for activation of the p70 S6 kinase, Mol. Cell. Biol., 15, 2333, 10.1128/MCB.15.5.2333 · DOI · Paper page
  113. Alessi, 1996, Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase, FEBS Lett., 399, 333, 10.1016/S0014-5793(96)01370-1 · DOI · Paper page
  114. Bruhn, 2010, Second AKT: the rise of SGK in cancer signalling, Growth Factors, 28, 394, 10.3109/08977194.2010.518616 · DOI · Paper page
  115. Sommer, 2013, Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors, Biochem. J., 452, 499, 10.1042/BJ20130342 · DOI
  116. Chun, 2002, The Na(+)/H(+) exchanger regulatory factor 2 mediates phosphorylation of serum- and glucocorticoid-induced protein kinase 1 by 3-phosphoinositide-dependent protein kinase 1, Biochem. Biophys. Res. Commun., 298, 207, 10.1016/S0006-291X(02)02428-2 · DOI
  117. Bayliss, 2003, Structural basis of Aurora-A activation by TPX2 at the mitotic spindle, Mol. Cell, 12, 851, 10.1016/S1097-2765(03)00392-7 · DOI · Paper page
  118. Elkins, 2012, Crystal structure of human Aurora B in complex with INCENP and VX-680, J. Med. Chem., 55, 7841, 10.1021/jm3008954 · doi:10.1021/jm3008954
  119. Otto, 2009, Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma, Cancer Cell, 15, 67, 10.1016/j.ccr.2008.12.005 · DOI · Paper page
  120. Gustafson, 2014, Drugging MYCN through an allosteric transition in Aurora kinase A, Cancer Cell, 26, 414, 10.1016/j.ccr.2014.07.015 · DOI · Paper page
  121. Dauch, 2016, A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer, Nat. Med., 22, 744, 10.1038/nm.4107 · DOI · Paper page
  122. Brockmann, 2013, Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma, Cancer Cell, 24, 75, 10.1016/j.ccr.2013.05.005 · DOI · Paper page
  123. Richards, 2016, Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors, Proc. Natl. Acad. Sci. U. S. A., 113, 13726, 10.1073/pnas.1610626113 · DOI · Paper page
  124. Zheng, 2016, Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype, Nat. Commun., 7, 10180, 10.1038/ncomms10180 · DOI · Paper page
  125. Burgess, 2016, Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain, Open Biol., 6, 10.1098/rsob.160089 · DOI
  126. Strebhardt, 2010, Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy, Nat. Rev. Drug Discov., 9, 643, 10.1038/nrd3184 · DOI · Paper page
  127. Raab, 2014, Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells, Cell Res., 24, 1141, 10.1038/cr.2014.86 · DOI
  128. Cheng, 2003, The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex, EMBO J., 22, 5757, 10.1093/emboj/cdg558 · DOI · Paper page
  129. Elia, 2003, The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain, Cell, 115, 83, 10.1016/S0092-8674(03)00725-6 · DOI · Paper page
  130. Xu, 2013, Structural basis for the inhibition of Polo-like kinase 1, Nat. Struct. Mol. Biol., 20, 1047, 10.1038/nsmb.2623 · DOI
  131. Zhu, 2016, Phospho-pon binding-mediated fine-tuning of Plk1 activity, Structure, 24, 1110, 10.1016/j.str.2016.04.012 · DOI
  132. Ni, 2015, Structural basis for Mob1-dependent activation of the core Mst-Lats kinase cascade in Hippo signaling, Genes Dev., 29, 1416, 10.1101/gad.264929.115 · DOI · Paper page
  133. Xiong, 2017, Regulation of Protein Interactions by Mps One Binder (MOB1) Phosphorylation, Mol. Cell Proteomics., 16, 1111, 10.1074/mcp.M117.068130 · DOI
  134. Kim, 2016, Structural basis for autoinhibition and its relief of MOB1 in the Hippo pathway, Sci. Rep., 6, 28488, 10.1038/srep28488 · DOI
  135. Rock, 2013, Activation of the yeast Hippo pathway by phosphorylation-dependent assembly of signaling complexes, Science, 340, 871, 10.1126/science.1235822 · DOI
  136. Gogl, 2015, The structure of an NDR/LATS kinase-mob complex reveals a novel kinase-coactivator system and substrate docking mechanism, PLoS Biol., 13, e1002146, 10.1371/journal.pbio.1002146 · DOI
  137. Street, 2011, Rho kinase proteins–pleiotropic modulators of cell survival and apoptosis, Anticancer Res., 31, 3645
  138. Jacobs, 2006, The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J. Biol. Chem., 281, 260, 10.1074/jbc.M508847200 · DOI · Paper page
  139. Heikkila, 2011, Co-crystal structures of inhibitors with MRCKbeta, a key regulator of tumor cell invasion, PLoS One, 6, e24825, 10.1371/journal.pone.0024825 · DOI
  140. Elkins, 2009, Structure of dystrophia myotonica protein kinase, Protein Sci., 18, 782, 10.1002/pro.82 · DOI
  141. Truebestein, 2015, A molecular ruler regulates cytoskeletal remodelling by the Rho kinases, Nat. Commun., 6, 10029, 10.1038/ncomms10029 · DOI
  142. Truebestein, 2016, Made to measure − keeping Rho kinase at a distance, Small GTPases, 7, 82, 10.1080/21541248.2016.1173770 · DOI
  143. Zhang, 2003, Homodimerization through coiled-coil regions enhances activity of the myotonic dystrophy protein kinase, FEBS Lett., 546, 281, 10.1016/S0014-5793(03)00601-X · DOI
  144. Gagliardi, 2014, PDK1-mediated activation of MRCKalpha regulates directional cell migration and lamellipodia retraction, J. Cell Biol., 206, 415, 10.1083/jcb.201312090 · DOI
  145. Pitcher, 1998, G protein-coupled receptor kinases, Annu. Rev. Biochem., 67, 653, 10.1146/annurev.biochem.67.1.653 · DOI · Paper page
  146. Nogués, 2017, G protein-coupled receptor kinases (GRKs) in tumorigenesis and cancer progression: GPCR regulators and signaling hubs, Semin. Cancer Biol.
  147. Lodowski, 2003, Keeping G proteins at bay: a complex between G protein-coupled receptor kinase 2 and Gbetagamma, Science, 300, 1256, 10.1126/science.1082348 · DOI · Paper page
  148. Boguth, 2010, Molecular basis for activation of G protein-coupled receptor kinases, EMBO J., 29, 3249, 10.1038/emboj.2010.206 · DOI
  149. Huang, 2011, Recognition in the face of diversity: interactions of heterotrimeric G proteins and G protein-coupled receptor (GPCR) kinases with activated GPCRs, J. Biol. Chem., 286, 7715, 10.1074/jbc.R109.051847 · DOI
  150. Huang, 2009, A surface of the kinase domain critical for the allosteric activation of G protein-coupled receptor kinases, J. Biol. Chem., 284, 17206, 10.1074/jbc.M809544200 · DOI
  151. Pao, 2009, Role of the amino terminus of G protein-coupled receptor kinase 2 in receptor phosphorylation, Biochemistry, 48, 7325, 10.1021/bi900408g · DOI
  152. Beautrait, 2014, Mapping the putative G protein-coupled receptor (GPCR) docking site on GPCR kinase 2: insights from intact cell phosphorylation and recruitment assays, J. Biol. Chem., 289, 25262, 10.1074/jbc.M114.593178 · DOI
  153. Sapio, 2014, Targeting protein kinase A in cancer therapy: an update, EXCLI J., 13, 843
  154. Francis, 2010, cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action, Pharmacol. Rev., 62, 525, 10.1124/pr.110.002907 · DOI · Paper page
  155. Browning, 2010, cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment, Fut. Med. Chem., 2, 65, 10.4155/fmc.09.142 · DOI
  156. Windham, 2015, cGMP signaling as a target for the prevention and treatment of breast cancer, Semin. Cancer Biol., 31, 106, 10.1016/j.semcancer.2014.06.006 · DOI
  157. Taylor, 2012, Assembly of allosteric macromolecular switches: lessons from PKA, Nat. Rev. Mol. Cell Biol., 13, 646, 10.1038/nrm3432 · DOI · Paper page
  158. Sjoberg, 2010, Dissecting the cAMP-inducible allosteric switch in protein kinase A RIalpha, Protein Sci., 19, 1213, 10.1002/pro.400 · DOI
  159. Kim, 2015, Dysfunctional conformational dynamics of protein kinase A induced by a lethal mutant of phospholamban hinder phosphorylation, Proc. Natl. Acad. Sci. U. S. A., 112, 3716, 10.1073/pnas.1502299112 · DOI · Paper page
  160. Francis, 2002, Mechanisms of autoinhibition in cyclic nucleotide-dependent protein kinases, Front. Biosci., 7, d580, 10.2741/A796 · doi:10.2741/a796
  161. Burgoyne, 2007, Cysteine redox sensor in PKGIa enables oxidant-induced activation, Science, 317, 1393, 10.1126/science.1144318 · DOI · Paper page
  162. Prysyazhna, 2012, Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension, Nat. Med., 18, 286, 10.1038/nm.2603 · DOI · Paper page
  163. Rudyk, 2012, Nitroglycerin fails to lower blood pressure in redox-dead Cys42Ser PKG1alpha knock-in mouse, Circulation, 126, 287, 10.1161/CIRCULATIONAHA.112.101287 · DOI
  164. Moon, 2013, The switch helix: a putative combinatorial relay for interprotomer communication in cGMP-dependent protein kinase, Biochim. Biophys. Acta, 1834, 1346, 10.1016/j.bbapap.2013.02.009 · doi:10.1016/j.bbapap.2013.02.009
  165. Antal, 2014, Intramolecular conformational changes optimize protein kinase C signaling, Chem. Biol., 21, 459, 10.1016/j.chembiol.2014.02.008 · DOI
  166. Sudol, 2010, Modularity in the Hippo signaling pathway, Trends Biochem. Sci., 35, 627, 10.1016/j.tibs.2010.05.010 · DOI · Paper page
  167. Zitouni, 2014, Polo-like kinases: structural variations lead to multiple functions, Nat. Rev. Mol. Cell Biol., 15, 433, 10.1038/nrm3819 · DOI · Paper page

Cited by

See all 159

Metadata

Authors
Leroux, A. E., Schulze, J. O., & Biondi, R. M.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2018-02
Volume
48
Pages
1-17
ISSN
1044-579X
Cited by
159
References
11
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Europrofession Foundation
  • University of Saarland, the University of Frankfurt
  • DFG
  • D-Krebshilfe
  • BMBF
  • CONICET
  • ANPCyT
  • FOCEM-Mercosur (COF 03/11)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AGC kinases, mechanisms of regulation and innovative drug development. https://app.cochat.ai/papers/10.1016/j.semcancer.2017.05.011
The paper
Leroux, A. E., Schulze, J. O., & Biondi, R. M. (2018). AGC kinases, mechanisms of regulation and innovative drug development. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2017.05.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.